Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Atricure (ATRC)
NASDAQ:ATRC
Holding ATRC?
Track your performance easily
ATRC Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$18.94 - $44.64
Previous Close$27.99
Volume80.33K
Average Volume (3M)847.41K
Market Cap
$1.40B
Enterprise Value$1.31B
Total Cash (Recent Filing)$114.02M
Total Debt (Recent Filing)$61.87M
Price to Earnings (P/E)―
Beta1.71
Next Earnings
Oct 30, 2024EPS Estimate
-$0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.86
Shares Outstanding48,697,505
10 Day Avg. Volume650,158
30 Day Avg. Volume847,409
Standard Deviation0.12
R-Squared0.36
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)2.95
Price to Sales (P/S)3.18
Price to Cash Flow (P/CF)46.30
P/FCF Ratio66.20
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.05
Enterprise Value/Gross Profit4.36
Enterprise Value/Ebitda-81.61
Forecast
1Y Price Target
$39.89Price Target Upside38.99% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Atricure News
Bulls Say, Bears Say
Bulls Say
Product LaunchAtriCure received FDA approval for the newest iteration of its clip, the Flex-Mini, and the impact from competition entering the LAA clipping market seems less than initially feared by investors.
Revenue GrowthHighly encouraged by the 17% Y/Y growth that AtriCure saw in its open appendage management franchise, which has been a focus on investors given Medtronic’s entrance to the field.
Technological AdvancementsThe company launched the cryoSphere+ in the US, which allows for a 25% reduction in freeze time – overcoming a key barrier to adoption and enables expansion into adjacent opportunities, like sternotomy.
Bears Say
Earnings PerformanceATRC's gross, operating, and adjusted EBITDA margins declined significantly, driven by geographic and product mix.
Product CompetitionConcerns persist about the impact of Medtronic's new surgical device on ATRC's US Appendage Management business.
Revenue GuidanceATRC trimmed its FY24 revenue guidance due to distractions from the ongoing rollout of new technology affecting anticipated growth.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ATRC FAQ
What was Atricure’s price range in the past 12 months?
Atricure lowest stock price was $18.94 and its highest was $44.64 in the past 12 months.
What is Atricure’s market cap?
Currently, no data Available
When is Atricure’s upcoming earnings report date?
Atricure’s upcoming earnings report date is Oct 30, 2024 which is in 41 days.
How were Atricure’s earnings last quarter?
Atricure released its earnings results on Jul 30, 2024. The company reported -$0.17 earnings per share for the quarter, missing the consensus estimate of -$0.168 by -$0.002.
Is Atricure overvalued?
According to Wall Street analysts Atricure’s price is currently Undervalued.
Does Atricure pay dividends?
Atricure does not currently pay dividends.
What is Atricure’s EPS estimate?
Atricure’s EPS estimate is -$0.2.
How many shares outstanding does Atricure have?
Atricure has 48,697,506 shares outstanding.
What happened to Atricure’s price movement after its last earnings report?
Atricure reported an EPS of -$0.17 in its last earnings report, missing expectations of -$0.168. Following the earnings report the stock price went down -1.955%.
Which hedge fund is a major shareholder of Atricure?
Among the largest hedge funds holding Atricure’s share is Royce & Associates LLC. It holds Atricure’s shares valued at 1M.
---
Atricure Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$39.89 (38.99% Upside)
$39.89 (38.99% Upside)
Blogger Sentiment
Bullish
ATRC Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 110.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $84.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 8.4%
Last 30 Days ▼ 8.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-35.59%
12-Months-Change
Fundamentals
Return on Equity
-8.68%
Trailing 12-Months
Asset Growth
0.52%
Trailing 12-Months
Company Description
Atricure
AtriCure, Inc. engages development, manufacture and sale of devices designed primarily for the surgical ablation of cardiac tissue, and systems for the exclusion of the left atrial appendage. Its products include radio Frequency (RF) ablation pacing and sensing, cryo, left atrial appendage management, soft tissue dissection, estech surgical instrumentation, and cart configuration. It operates through the following geographical segments: United States, Europe, Asia, Other International, and Total International. The company was founded by Michael D. Hooven on October 31, 2000 and is headquartered in West Chester, OH.
---
ATRC Company Deck
---
ATRC Earnings Call
Q2 2024
0:00 / 0:00
---
ATRC Stock 12 Month Forecast
Average Price Target
$39.89
▲(38.99% Upside)
Technical Analysis
Best Analysts Covering ATRC
1 Year
1 Year Success Rate
19/21 ratings generated profit
1 Year Average Return
+43.11%
reiterated a buy rating 2 months ago
Copying Suraj Kalia's trades and holding each position for 1 Year would result in 90.48% of your transactions generating a profit, with an average return of +43.11% per trade.
---